Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy

2015 ◽  
Vol 20 (8) ◽  
pp. 849-854 ◽  
Author(s):  
Gregory D Huhn ◽  
Andrew Sigman ◽  
Britt Livak
Keyword(s):  
Antiretroviral Therapy ◽  
Randomized Trial ◽  
Once Daily ◽  
Hiv 1

scholarly journals Simplification Therapy with Once‐Daily Emtricitabine, Didanosine, and Efavirenz in HIV‐1–Infected Adults with Viral Suppression Receiving a Protease Inhibitor–Based Regimen: A Randomized Trial

2005 ◽  
Vol 191 (6) ◽  
pp. 830-839 ◽  
Author(s):  
Jean‐Michel Molina ◽  
Valérie Journot ◽  
Laurence Morand‐Joubert ◽  
Patrick Yéni ◽  
Willy Rozenbaum ◽  
...  
Keyword(s):  
Protease Inhibitor ◽  
Randomized Trial ◽  
Viral Suppression ◽  
Once Daily ◽  
Hiv 1

scholarly journals High Treatment Success Rates When Switching to Once Daily Nevirapine Containing Antiretroviral Therapy

2008 ◽  
Vol 2 (1) ◽  
pp. 89-93 ◽  
Author(s):  
Andrew Benzie ◽  
Brett Marett ◽  
Nicola E Mackie ◽  
Alan Winston
Keyword(s):  
Antiretroviral Therapy ◽  
Treatment Success ◽  
First Year ◽  
Success Rates ◽  
Once Daily ◽  
Hiv Rna ◽  
Virological Outcome ◽  
Treatment Naïve ◽  
High Treatment ◽  
Hiv 1

Introduction Two recent studies have highlighted low rates of virological response to once daily nevirapine containing combination antiretroviral therapy (CART) in treatment naïve HIV-1 infected subjects. Aim We assessed factors associated with treatment responses in a cohort of HIV-1 infected, therapy naïve individuals, commencing nevirapine CART with two nucleoside reverse transcriptase inhibitors (NRTI) containing either lamivudine or emtricitabine. Results Between January 2002 and 2006, 173 subjects (80 female) met the study inclusion criteria. All subjects initially commenced on twice daily nevirapine with six different NRTI backbones. Mean follow up was 802 days. 49 (28%) subjects switched to once daily nevirapine, 23 (13%) within the first year. After 48 weeks of therapy, HIV RNA was < 50 copies/mL in 154/173 subjects (89%). A trend was observed towards improved virological outcome (HIV RNA < 50 copies/mL) and switching to once daily nevirapine during the first year of therapy (p=0.051). Conclusion Whilst awaiting the results of prospective studies assessing once daily nevirapine, our data describe high treatment success rates and good safety responses when switching to once daily nevirapine.

scholarly journals Suppression of Virus Load by Highly Active Antiretroviral Therapy in Rhesus Macaques Infected with a Recombinant Simian Immunodeficiency Virus Containing Reverse Transcriptase from Human Immunodeficiency Virus Type 1

2005 ◽  
Vol 79 (12) ◽  
pp. 7349-7354 ◽  
Author(s):  
Thomas W. North ◽  
Koen K. A. Van Rompay ◽  
Joanne Higgins ◽  
Timothy B. Matthews ◽  
Debra A. Wadford ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Antiretroviral Therapy ◽  
Reverse Transcriptase ◽  
Highly Active Antiretroviral Therapy ◽  
Rhesus Macaques ◽  
Once Daily ◽  
Highly Active ◽  
Immunodeficiency Virus ◽  
Hiv 1

ABSTRACT We have modeled highly active antiretroviral therapy (HAART) for AIDS in rhesus macaques infected with a chimera (RT-SHIV) of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type-1 (HIV-1). Seven RT-SHIV-infected macaques were treated with a combination of efavirenz (200 mg orally once daily), lamivudine (8 mg/kg subcutaneously once daily), and tenofovir (30 mg/kg subcutaneously once daily). Plasma viral RNA levels in all animals were reduced by more than 1,000-fold after 4 weeks and, in six of the seven animals, were reduced to undetectable levels after 10 weeks. Virus loads increased slightly between 12 and 16 weeks of treatment, associated with problems with the administration of efavirenz. After a change in the method of efavirenz administration, virus loads declined again and remained undetectable in the majority of animals for the duration of therapy. Treatment was stopped for three animals after 36 weeks of therapy, and virus loads increased rapidly. Posttreatment RT-SHIV isolates had no mutations associated with resistance to any of the three drugs. Efavirenz treatment was stopped, but lamivudine and tenofovir treatment for two other macaques was continued. The virus load in one of these two animals rebounded; virus from this animal was initially free of drug-resistance mutations but acquired the K65R mutation in reverse transcriptase at 11 weeks after efavirenz treatment was withdrawn. These results mimic HAART of HIV-1-infected humans. The RT-SHIV/rhesus macaque model should be useful for studies of tissue reservoirs and sites of residual replication that are not possible or practical with humans.

scholarly journals 543. An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults

2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S201-S202 ◽  
Author(s):  
Melanie Thompson ◽  
Chloe Orkin ◽  
Jean-Michel Molina ◽  
Jose Gatell ◽  
Paul Sax ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Safety Analysis ◽  
Once Daily ◽  
Hiv 1

scholarly journals No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial

2019 ◽  
Vol 6 (3) ◽  
Author(s):  
Jonathan Z Li ◽  
Paul E Sax ◽  
Vincent C Marconi ◽  
Jesse Fajnzylber ◽  
Baiba Berzins ◽  
...  
Keyword(s):  
Viral Load ◽  
Antiretroviral Therapy ◽  
Viral Replication ◽  
Randomized Trial ◽  
Viral Suppression ◽  
Group Differences ◽  
Residual Viremia ◽  
Ultrasensitive Assay ◽  
Hiv 1

Abstract In the ASPIRE trial, antiretroviral therapy (ART) switch to dolutegravir plus lamivudine (DTG+3TC) was comparable to 3-drug ART in maintaining viral suppression by standard viral load assays. We used an ultrasensitive assay to assess whether this switch led to increased residual viremia. At entry, levels of residual viremia did not differ significantly between arms (DTG+3TC vs 3-drug ART: mean, 5.0 vs 4.2 HIV-1 RNA copies/mL; P = .64). After randomization, no significant between-group differences were found at either week 24 or 48. These results show no evidence for increased viral replication on DTG+3TC and support its further investigation as a dual ART strategy.

Sign in / Sign up

Export Citation Format

Share Document